Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

Loss of ambulation in SMA III at the time of disease-modifying treatments: an international study.

Loss of ambulation in SMA III at the time of disease-modifying treatments: an international study. Journal of neurology, neurosurgery, and psychiatry Coratti, G., Bovis, F., Franchino, V., Montes, J., Sansone, V. A., Dunaway Young, S., Cutrì, C., Pasternak, A., Pera, M. C., Pane, M., Glanzman, A., Pegoraro, E., Duong, T., Sogus, E., Sframeli, M., Messina, S., Cavalcante, E., Scoto, M. C., D'Amico, A., Rodriguez-Torres, R., Mongini, T., Maggi, L., Coccia, M., Filosto, M., Zuccarino, R., Masson, R., Ricci, G., Bruno, C., Ruggiero, L., Vacchiano, V., D'errico, E., Verriello, L., Nigro, V., Scarpini, G., Garibaldi, M., Turri, M., Ticci, C., Berardinelli, A., Agosto, C., Ricci, F., Zolkipli-Cunningham, Z., Darras, B. T., Day, J., Hirano, M., Muntoni, F., Finkel, R. S., Mercuri, E. 2026

Abstract

Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder caused by survival motor neuron (SMN1) deletion. While loss of ambulation in SMA type III typically occurs at a median age of 13.4 years, outcomes in the treatment era remain unclear. This study aims to address that gap by investigating ambulation outcomes in individuals with type III receiving disease-modifying therapies.This retrospective study analysed prospectively collected international data. Time-dependent Cox models assessed the association between treatment initiation and age at loss of ambulation, adjusting for age at onset, sex, SMN2 copies, birth year and country. Treatment was modelled as a time-dependent covariate to avoid immortal time bias. Descriptive analyses used Mann-Whitney U and ?² tests.Among 555 individuals with type III, treatment halved the risk of ambulation loss (HR=0.50), with median loss at 44 vs 32 years in treated and untreated groups. Later onset, =4 SMN2 copies and female sex were also protective. The treatment effect was significant in type IIIA (HR=0.34) but not IIIB, with no significant interactions by sex, country or SMN2, though effects remained directionally protective.Treatment in type III reduced the risk of ambulation loss by 50%, extending median ambulation by 12 years, with the greatest benefit in type IIIA. Later onset, female sex and higher SMN2 copy number were also protective but did not modify treatment effect. These findings underscore the value of early treatment and support its broad use to preserve ambulation across clinical subgroups.

View details for DOI 10.1136/jnnp-2025-337505

View details for PubMedID 41617535